1. Home
  2. Labeler Index
  3. Taro Pharmaceuticals U.s.a., Inc.
  4. 51672-1374
  5. NDC Package Code: 51672-1374-2 Tazarotene

NDC Package 51672-1374-2 Tazarotene

Cream Topical - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
51672-1374-2
Package Description:
1 TUBE in 1 CARTON / 30 g in 1 TUBE
Product Code:
51672-1374
Proprietary Name:
Tazarotene
Non-Proprietary Name:
Tazarotene
Substance Name:
Tazarotene
Usage Information:
Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.
11-Digit NDC Billing Format:
51672137402
NDC to RxNorm Crosswalk:
  • RxCUI: 313200 - tazarotene 0.1 % Topical Cream
  • RxCUI: 313200 - tazarotene 1 MG/ML Topical Cream
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Taro Pharmaceuticals U.s.a., Inc.
    Dosage Form:
    Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
    Administration Route(s):
  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
    • Active Ingredient(s):
  • TAZAROTENE 1 mg/g
    • Pharmacologic Class(es):
  • Retinoid - [EPC] (Established Pharmacologic Class)
  • Retinoids - [CS]
    • Sample Package:
    No
    FDA Application Number:
    ANDA208258
    Marketing Category:
    ANDA - A product marketed under an approved Abbreviated New Drug Application.
    Start Marketing Date:
    04-03-2017
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 51672-1374-2?

    The NDC Packaged Code 51672-1374-2 is assigned to a package of 1 tube in 1 carton / 30 g in 1 tube of Tazarotene, a human prescription drug labeled by Taro Pharmaceuticals U.s.a., Inc.. The product's dosage form is cream and is administered via topical form.

    Is NDC 51672-1374 included in the NDC Directory?

    Yes, Tazarotene with product code 51672-1374 is active and included in the NDC Directory. The product was first marketed by Taro Pharmaceuticals U.s.a., Inc. on April 03, 2017 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 51672-1374-2?

    The 11-digit format is 51672137402. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-4-151672-1374-25-4-251672-1374-02